Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report

A 62-year-old woman received RBX2660, an investigational microbiome restoration therapeutic, for recurrent multidrug-resistant (MDR) urinary tract infection (UTI). RBX2660 increased gut microbiome diversity but did not eliminate uropathogen carriage, and MDR UTI recurred after subsequent antibiotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Keen, Eric C, Tasoff, Preston, Hink, Tiffany, Reske, Kimberly A, Burnham, Carey-Ann D, Dantas, Gautam, Kwon, Jennie H, Dubberke, Erik R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report (Fast track - FIDSA members only)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052748/
https://www.ncbi.nlm.nih.gov/pubmed/32154322
http://dx.doi.org/10.1093/ofid/ofaa042
Descripción
Sumario:A 62-year-old woman received RBX2660, an investigational microbiome restoration therapeutic, for recurrent multidrug-resistant (MDR) urinary tract infection (UTI). RBX2660 increased gut microbiome diversity but did not eliminate uropathogen carriage, and MDR UTI recurred after subsequent antibiotic exposure. Thus, restoration of microbiome diversity does not preclude disease recurrence by residual MDR pathogens.

Ejemplares similares